Provided by Tiger Trade Technology Pte. Ltd.

Amneal Pharmaceuticals, Inc.

14.52
-0.2500-1.69%
Post-market: 14.36-0.1616-1.11%19:38 EST
Volume:3.19M
Turnover:46.79M
Market Cap:4.56B
PE:902.37
High:14.99
Open:14.89
Low:14.49
Close:14.77
52wk High:15.00
52wk Low:6.69
Shares:314.36M
Float Shares:168.50M
Volume Ratio:1.12
T/O Rate:1.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0161
EPS(LYR):-0.3783
ROE:-881.26%
ROA:6.79%
PB:-41.70
PE(LYR):-38.38

Loading ...

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and Xgeva®

THOMSON REUTERS
·
Dec 23, 2025

Amneal Pharma - Expects to Commercialize Six Biosimilars by 2027

THOMSON REUTERS
·
Dec 23, 2025

FDA Approves Amneal and mAbxience Denosumab Biosimilars

Reuters
·
Dec 23, 2025

Amneal Pharmaceuticals (AMRX): Valuation Check After FDA Approval for New Epinephrine Injection

Simply Wall St.
·
Dec 21, 2025

The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following FDA Green Light For Hospital Epinephrine

Simply Wall St.
·
Dec 19, 2025

The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following Key FDA Wins For Epinephrine And Complex Generics

Simply Wall St.
·
Dec 11, 2025

FDA Approves Amneal Epinephrine Injection for U.S. Hospitals

Reuters
·
Dec 10, 2025

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

THOMSON REUTERS
·
Dec 10, 2025

Amneal Pharmaceuticals Initiated at Overweight by Barclays

Dow Jones
·
Dec 09, 2025

U.S. RESEARCH ROUNDUP-AstraZeneca, Confluent, Pepsico

Reuters
·
Dec 09, 2025

Amneal Reports Positive Interim Results for CREXONT in Parkinson’s Disease Trial

Reuters
·
Dec 05, 2025

Amneal Announces Positive Interim Phase 4 Elevate-Pd Results With Crexont® for Parkinson’s Disease

THOMSON REUTERS
·
Dec 05, 2025

Amneal Pharma: Elevate-Pd Study Is Ongoing With Longer-Term Data Expected in 2026

THOMSON REUTERS
·
Dec 05, 2025

Amneal Pharma - 55 Patients Show Substantial Benefit With Crexont

THOMSON REUTERS
·
Dec 05, 2025

A Look at Amneal Pharmaceuticals’ Valuation as New FDA Generics to Restasis and ProAir HFA Expand Growth Prospects

Simply Wall St.
·
Dec 05, 2025

AT&T sues generic drugmakers over alleged price-fixing scheme

Reuters
·
Dec 04, 2025

FDA Approval for Generic Restasis Might Change the Case for Investing in Amneal Pharmaceuticals (AMRX)

Simply Wall St.
·
Dec 03, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Cloudflare, Boeing

Reuters
·
Dec 02, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Janux Therapeutics, Bunge Global, Shopify

Reuters
·
Dec 02, 2025

Amneal Pharmaceuticals to Present at Piper Sandler and J.P. Morgan Healthcare Conferences

Reuters
·
Dec 02, 2025